The role of CD68+ macrophage in classical Hodgkin lymphoma patients from Egypt
Abstract Background CD68+ tumor-associated macrophages (TAM) play an important role in the progression of classical Hodgkin lymphoma (cHL). We assessed the role of CD20 and CD68 + TAM in a cohort of cHL patients from Egypt and correlated the number of CD68 + cells with patients’ characteristics, res...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-02-01
|
Series: | Diagnostic Pathology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13000-019-0912-3 |
id |
doaj-a3a8a1500d66402986724280f29a6083 |
---|---|
record_format |
Article |
spelling |
doaj-a3a8a1500d66402986724280f29a60832021-02-07T12:24:24ZengBMCDiagnostic Pathology1746-15962020-02-0115111310.1186/s13000-019-0912-3The role of CD68+ macrophage in classical Hodgkin lymphoma patients from EgyptOsama Mohamed0Ahmed El Bastawisy1Nasr Allahlobi2Mona S. Abdellateif3Abdel Rahman N. Zekri4Sabry Shaarawy5Zeinab Korany6Marwa Mohanad7Abeer A. Bahnassy8Department of Medical Oncology, National Cancer Institute, Cairo UniversityDepartment of Medical Oncology, National Cancer Institute, Cairo UniversityDepartment of Medical Oncology, National Cancer Institute, Cairo UniversityMedical Biochemistry and molecular biology, Cancer Biology Department, National Cancer Institute, Cairo UniversityMolecular Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo UniversityMedical Biochemistry and molecular biology, Cancer Biology Department, National Cancer Institute, Cairo UniversityMedical Biochemistry and molecular biology, Cancer Biology Department, National Cancer Institute, Cairo UniversityBiochemistry Department, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and TechnologyPathology Department, National Cancer Institute, Cairo UniversityAbstract Background CD68+ tumor-associated macrophages (TAM) play an important role in the progression of classical Hodgkin lymphoma (cHL). We assessed the role of CD20 and CD68 + TAM in a cohort of cHL patients from Egypt and correlated the number of CD68 + cells with patients’ characteristics, response to treatment, overall and progression free survival rates (OS & PFS). Methods CD20 expression and CD68 + TAM numbers were assessed in representative tumor tissues obtained from 81 cHL patients using flowcytometry (FCM), immunohistochemistry (IHC), and Rt-PCR techniques. Results The expression levels of CD68 protein by IHC was high in 27 (33.3%), moderate in 15 (18.5%), low in 15 (18.5%), and negative in 24 (29.6%) patients (p = 0.13). CD68-mRNA expression was high in 43/81(53.1%), and low in 38(46.9%) patients (p = 0.6). The number of CD68 + TAM (by FCM) was low (< 20 cells) in 42/81 (51.9%), and high (≥20 cells) in 39/81 (48.1%) patients (p = 0.74). CD68 expression (by FCM, IHC& Rt-PCR) associated significantly with poor response to treatment, decreased CD20 expression, reduced OS and PFS rates (p < 0.001 for all). CD68 expression (by Rt-PCR only) associated significantly with advanced disease stage (p = 0.04). The age of the patients, high CD20 expression & high CD68+ macrophage number were independent prognostic factors for OS (p= 0.02, p = 0.008 & p = 0.009; respectively). However, the age of the patient, high CD20, and high CD68+ macrophage expression (by FCM&IHC) were independent prognostic factors for DFS (p. = 0.004, p. = 0.01, p. = 0.007 and p. = 0.01; respectively). Conclusion CD68 + TAM expression (by Rt-PCR, FCM and/or IHC) can identify patients with poor response to treatment and reduced survival rates (OS& PFS). Assessment of CD68 + positive macrophages by FCM is superior to other methods (Rt-PCR and IHC) as a prognostic factor for DFS and OS rates.https://doi.org/10.1186/s13000-019-0912-3cHLTAMCD68CD20SurvivalPrognosis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Osama Mohamed Ahmed El Bastawisy Nasr Allahlobi Mona S. Abdellateif Abdel Rahman N. Zekri Sabry Shaarawy Zeinab Korany Marwa Mohanad Abeer A. Bahnassy |
spellingShingle |
Osama Mohamed Ahmed El Bastawisy Nasr Allahlobi Mona S. Abdellateif Abdel Rahman N. Zekri Sabry Shaarawy Zeinab Korany Marwa Mohanad Abeer A. Bahnassy The role of CD68+ macrophage in classical Hodgkin lymphoma patients from Egypt Diagnostic Pathology cHL TAM CD68 CD20 Survival Prognosis |
author_facet |
Osama Mohamed Ahmed El Bastawisy Nasr Allahlobi Mona S. Abdellateif Abdel Rahman N. Zekri Sabry Shaarawy Zeinab Korany Marwa Mohanad Abeer A. Bahnassy |
author_sort |
Osama Mohamed |
title |
The role of CD68+ macrophage in classical Hodgkin lymphoma patients from Egypt |
title_short |
The role of CD68+ macrophage in classical Hodgkin lymphoma patients from Egypt |
title_full |
The role of CD68+ macrophage in classical Hodgkin lymphoma patients from Egypt |
title_fullStr |
The role of CD68+ macrophage in classical Hodgkin lymphoma patients from Egypt |
title_full_unstemmed |
The role of CD68+ macrophage in classical Hodgkin lymphoma patients from Egypt |
title_sort |
role of cd68+ macrophage in classical hodgkin lymphoma patients from egypt |
publisher |
BMC |
series |
Diagnostic Pathology |
issn |
1746-1596 |
publishDate |
2020-02-01 |
description |
Abstract Background CD68+ tumor-associated macrophages (TAM) play an important role in the progression of classical Hodgkin lymphoma (cHL). We assessed the role of CD20 and CD68 + TAM in a cohort of cHL patients from Egypt and correlated the number of CD68 + cells with patients’ characteristics, response to treatment, overall and progression free survival rates (OS & PFS). Methods CD20 expression and CD68 + TAM numbers were assessed in representative tumor tissues obtained from 81 cHL patients using flowcytometry (FCM), immunohistochemistry (IHC), and Rt-PCR techniques. Results The expression levels of CD68 protein by IHC was high in 27 (33.3%), moderate in 15 (18.5%), low in 15 (18.5%), and negative in 24 (29.6%) patients (p = 0.13). CD68-mRNA expression was high in 43/81(53.1%), and low in 38(46.9%) patients (p = 0.6). The number of CD68 + TAM (by FCM) was low (< 20 cells) in 42/81 (51.9%), and high (≥20 cells) in 39/81 (48.1%) patients (p = 0.74). CD68 expression (by FCM, IHC& Rt-PCR) associated significantly with poor response to treatment, decreased CD20 expression, reduced OS and PFS rates (p < 0.001 for all). CD68 expression (by Rt-PCR only) associated significantly with advanced disease stage (p = 0.04). The age of the patients, high CD20 expression & high CD68+ macrophage number were independent prognostic factors for OS (p= 0.02, p = 0.008 & p = 0.009; respectively). However, the age of the patient, high CD20, and high CD68+ macrophage expression (by FCM&IHC) were independent prognostic factors for DFS (p. = 0.004, p. = 0.01, p. = 0.007 and p. = 0.01; respectively). Conclusion CD68 + TAM expression (by Rt-PCR, FCM and/or IHC) can identify patients with poor response to treatment and reduced survival rates (OS& PFS). Assessment of CD68 + positive macrophages by FCM is superior to other methods (Rt-PCR and IHC) as a prognostic factor for DFS and OS rates. |
topic |
cHL TAM CD68 CD20 Survival Prognosis |
url |
https://doi.org/10.1186/s13000-019-0912-3 |
work_keys_str_mv |
AT osamamohamed theroleofcd68macrophageinclassicalhodgkinlymphomapatientsfromegypt AT ahmedelbastawisy theroleofcd68macrophageinclassicalhodgkinlymphomapatientsfromegypt AT nasrallahlobi theroleofcd68macrophageinclassicalhodgkinlymphomapatientsfromegypt AT monasabdellateif theroleofcd68macrophageinclassicalhodgkinlymphomapatientsfromegypt AT abdelrahmannzekri theroleofcd68macrophageinclassicalhodgkinlymphomapatientsfromegypt AT sabryshaarawy theroleofcd68macrophageinclassicalhodgkinlymphomapatientsfromegypt AT zeinabkorany theroleofcd68macrophageinclassicalhodgkinlymphomapatientsfromegypt AT marwamohanad theroleofcd68macrophageinclassicalhodgkinlymphomapatientsfromegypt AT abeerabahnassy theroleofcd68macrophageinclassicalhodgkinlymphomapatientsfromegypt AT osamamohamed roleofcd68macrophageinclassicalhodgkinlymphomapatientsfromegypt AT ahmedelbastawisy roleofcd68macrophageinclassicalhodgkinlymphomapatientsfromegypt AT nasrallahlobi roleofcd68macrophageinclassicalhodgkinlymphomapatientsfromegypt AT monasabdellateif roleofcd68macrophageinclassicalhodgkinlymphomapatientsfromegypt AT abdelrahmannzekri roleofcd68macrophageinclassicalhodgkinlymphomapatientsfromegypt AT sabryshaarawy roleofcd68macrophageinclassicalhodgkinlymphomapatientsfromegypt AT zeinabkorany roleofcd68macrophageinclassicalhodgkinlymphomapatientsfromegypt AT marwamohanad roleofcd68macrophageinclassicalhodgkinlymphomapatientsfromegypt AT abeerabahnassy roleofcd68macrophageinclassicalhodgkinlymphomapatientsfromegypt |
_version_ |
1724281247276990464 |